Implications for oxidative stress and astrocytes following 26S proteasomal depletion in mouse forebrain neurones

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 12, 2013, Pages 1930-1938

  Elkharaz, Jamal ^a   Ugun Klusek, Aslihan ^b   Constantin Teodosiu, Dumitru ^a   Lawler, Karen ^a   Mayer, R John ^a   Billett, Ellen ^b   Lowe, James ^a   Bedford, Lynn ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

26S proteasome; Astrocytes; Neurodegeneration; Oxidative stress; Peroxiredoxin 6; Ubiquitin proteasome system

Indexed keywords

26S PROTEASOME; PEROXIDASE; PEROXIREDOXIN 6; PHOSPHOLIPASE A2; PROTEASOME; UNCLASSIFIED DRUG; ATP DEPENDENT 26S PROTEASE; REACTIVE OXYGEN METABOLITE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN NERVE CELL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FLUORESCENCE ANALYSIS; FOREBRAIN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING; ANIMAL; CHEMISTRY; ENZYME IMMUNOASSAY; LIPID PEROXIDATION; MASS SPECTROMETRY; METABOLISM; NERVE CELL; PATHOLOGY;

MAMMALIA;

ANIMALS; ASTROCYTES; BLOTTING, WESTERN; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; IMMUNOENZYME TECHNIQUES; LIPID PEROXIDATION; MICE; NERVE DEGENERATION; NEURONS; OXIDATIVE STRESS; PHOSPHOLIPASES A2; PROSENCEPHALON; PROTEASOME ENDOPEPTIDASE COMPLEX; REACTIVE OXYGEN SPECIES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84894450673     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.07.002     Document Type: Article

References (81)

1. Schapira A.H., Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov. Disord. 2011, 26:1049-1055.
2. Leuner K., Muller W.E., Reichert A.S. From mitochondrial dysfunction to amyloid beta formation: novel insights into the pathogenesis of Alzheimer's disease. Mol. Neurobiol. 2012, 46:186-193.
3. Morawe T., Hiebel C., Kern A., Behl C. Protein homeostasis, aging and Alzheimer's disease. Mol. Neurobiol. 2012, 46:41-54.
4. Croisier E., Graeber M.B. Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration. Acta Neuropathol. 2006, 112:517-530.
5. Goldberg A.L. Protein degradation and protection against misfolded or damaged proteins. Nature 2003, 426:895-899.
6. Lowe J., Blanchard A., Morrell K., Lennox G., Reynolds L., Billett M., Landon M., Mayer R.J. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and Mallory bodies in alcoholic liver disease. J. Pathol. 1988, 155:9-15.
7. Ebrahimi-Fakhari D., Wahlster L., McLean P.J. Protein degradation pathways in Parkinson's disease: curse or blessing. Acta Neuropathol. 2012, 124:153-172.
8. Dennissen F.J., Kholod N., van Leeuwen F.W. The ubiquitin proteasome system in neurodegenerative diseases: culprit, accomplice or victim?. Prog. Neurobiol. 2012, 96:190-207.
9. Orre M., Kamphuis W., Dooves S., Kooijman L., Chan E.T., Kirk C.J., Dimayuga Smith V., Koot S., Mamber C., Jansen A.H., Ovaa H., Hol E.M. Reactive glia show increased immunoproteasome activity in Alzheimer's disease. Brain 2013, 136:1415-1431.
10. Bedford L., Hay D., Devoy A., Paine S., Powe D.G., Seth R., Gray T., Topham I., Fone K., Rezvani N., Mee M., Soane T., Layfield R., Sheppard P.W., Ebendal T., Usoskin D., Lowe J., Mayer R.J. Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J. Neurosci. 2008, 28:8189-8198.
11. Mayford M., Bach M.E., Huang Y.Y., Wang L., Hawkins R.D., Kandel E.R. Control of memory formation through regulated expression of a CaMKII transgene. Science 1996, 274:1678-1683.
12. Tsien J.Z., Chen D.F., Gerber D., Tom C., Mercer E.H., Anderson D.J., Mayford M., Kandel E.R., Tonegawa S. Subregion- and cell type-restricted gene knockout in mouse brain. Cell 1996, 87:1317-1326.
13. Erdelmeier I., Gerard-Monnier D., Yadan J.C., Chaudiere J. Reactions of N-methyl-2-phenylindole with malondialdehyde and 4-hydroxyalkenals. Mechanistic aspects of the colorimetric assay of lipid peroxidation. Chem. Res. Toxicol. 1998, 11:1184-1194.
14. Fisher A.B., Dodia C., Chander A., Jain M. A competitive inhibitor of phospholipase A2 decreases surfactant phosphatidylcholine degradation by the rat lung. Biochem. J. 1992, 288(Pt 2):407-411.
15. Fisher A.B., Dodia C. Role of phospholipase A2 enzymes in degradation of dipalmitoylphosphatidylcholine by granular pneumocytes. J. Lipid Res. 1996, 37:1057-1064.
16. Pekny M., Nilsson M. Astrocyte activation and reactive gliosis. Glia 2005, 50:427-434.
17. Manevich Y., Sweitzer T., Pak J.H., Feinstein S.I., Muzykantov V., Fisher A.B. 1-Cys peroxiredoxin overexpression protects cells against phospholipid peroxidation-mediated membrane damage. PNAS 2002, 99:11599-11604.
18. Wang X., Phelan S.A., Forsman-Semb K., Taylor E.F., Petros C., Brown A., Lerner C.P., Paigen B. Mice with targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress. J. Biol. Chem. 2003, 278:25179-25190.
19. Wang Y., Feinstein S.I., Manevich Y., Ho Y.S., Fisher A.B. Lung injury and mortality with hyperoxia are increased in peroxiredoxin 6 gene-targeted mice. Free Radic. Biol. Med. 2004, 37:1736-1743.
20. Wang Y., Feinstein S.I., Manevich Y., Ho Y.S., Fisher A.B. Peroxiredoxin 6 gene-targeted mice show increased lung injury with paraquat-induced oxidative stress. Antioxid. Redox Signal. 2006, 8:229-237.
21. Wang Y., Phelan S.A., Manevich Y., Feinstein S.I., Fisher A.B. Transgenic mice overexpressing peroxiredoxin 6 show increased resistance to lung injury in hyperoxia. Am. J. Respir. Cell Mol. Biol. 2006, 34:481-486.
22. 2-induced oxidative stress. J. Cell. Biochem. 2008, 104:1274-1285.
23. Jourdain L., Curmi P., Sobel A., Pantaloni D., Carlier M.F. Stathmin: a tubulin-sequestering protein which forms a ternary T2S complex with two tubulin molecules. Biochemistry 1997, 36:10817-10821.
24. Middeldorp J., Hol E.M. GFAP in health and disease. Prog. Neurobiol. 2011, 93:421-443.
25. Kamphuis W., Mamber C., Moeton M., Kooijman L., Sluijs J.A., Jansen A.H., Verveer M., de Groot L.R., Smith V.D., Rangarajan S., Rodriguez J.J., Orre M., Hol E.M. GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS One 2012, 7:e42823.
26. Zoltewicz J.S., Scharf D., Yang B., Chawla A., Newsom K.J., Fang L. Characterization of antibodies that detect human GFAP after traumatic brain injury. Biomark. Insights 2012, 7:71-79.
27. Kalyanaraman B., Darley-Usmar V., Davies K.J., Dennery P.A., Forman H.J., Grisham M.B., Mann G.E., Moore K., Roberts L.J., Ischiropoulos H. Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. Free Radic. Biol. Med. 2012, 52:1-6.
28. Freeman B.A., Crapo J.D. Biology of disease: free radicals and tissue injury. Lab. Invest. 1982, 47:412-426.
29. Slater T.F. Free-radical mechanisms in tissue injury. Biochem. J. 1984, 222:1-15.
30. Fisher A.B. Peroxiredoxin 6: a bifunctional enzyme with glutathione peroxidase and phospholipase A(2) activities. Antioxid. Redox Signal. 2011, 15:831-844.
31. Sofroniew M.V., Vinters H.V. Astrocytes: biology and pathology. Acta Neuropathol. 2010, 119:7-35.
32. Gandhi S., Abramov A.Y. Mechanism of oxidative stress in neurodegeneration. Oxid. Med. Cell. Longev. 2012, 2012:11. (Article ID 428010).
33. Varcin M., Bentea E., Michotte Y., Sarre S. Oxidative stress in genetic mouse models of Parkinson's disease. Oxid. Med. Cell. Longev. 2012, 2012:25. (Article ID 624925).
34. Andersen J.K. Oxidative stress in neurodegeneration: cause or consequence?. Nat. Med. 2004, 10:S18-25. (Suppl.).
35. Pratico D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Ann. N. Y. Acad. Sci. 2008, 1147:70-78.
36. Fisher A.B., Dodia C., Manevich Y., Chen J.W., Feinstein S.I. Phospholipid hydroperoxides are substrates for non-selenium glutathione peroxidase. J. Biol. Chem. 1999, 274:21326-21334.
37. Manevich Y., Shuvaeva T., Dodia C., Kazi A., Feinstein S.I., Fisher A.B. Binding of peroxiredoxin 6 to substrate determines differential phospholipid hydroperoxide peroxidase and phospholipase A(2) activities. Arch. Biochem. Biophys. 2009, 485:139-149.
38. Jain M.K., Yu B.Z., Rogers J., Ranadive G.N., Berg O.G. Interfacial catalysis by phospholipase A2: dissociation constants for calcium, substrate, products, and competitive inhibitors. Biochemistry 1991, 30:7306-7317.
39. Leavey P.J., Gonzalez-Aller C., Thurman G., Kleinberg M., Rinckel L., Ambruso D.W., Freeman S., Kuypers F.A., Ambruso D.R. A 29-kDa protein associated with p67phox expresses both peroxiredoxin and phospholipase A2 activity and enhances superoxide anion production by a cell-free system of NADPH oxidase activity. J. Biol. Chem. 2002, 277:45181-45187.
40. Chatterjee S., Feinstein S.I., Dodia C., Sorokina E., Lien Y.C., Nguyen S., Debolt K., Speicher D., Fisher A.B. Peroxiredoxin 6 phosphorylation and subsequent phospholipase A2 activity are required for agonist-mediated activation of NADPH oxidase in mouse pulmonary microvascular endothelium and alveolar macrophages. J. Biol. Chem. 2011, 286:11696-11706.
41. Kim S.Y., Chun E., Lee K.Y. Phospholipase A(2) of peroxiredoxin 6 has a critical role in tumor necrosis factor-induced apoptosis. Cell Death Differ. 2011, 18:1573-1583.
42. Ambruso D.R., Ellison M.A., Thurman G.W., Leto T.L. Peroxiredoxin 6 translocates to the plasma membrane during neutrophil activation and is required for optimal NADPH oxidase activity. Biochim. Biophys. Acta 2012, 1823:306-315.
43. Lien Y.C., Feinstein S.I., Dodia C., Fisher A.B. The roles of peroxidase and phospholipase A2 activities of peroxiredoxin 6 in protecting pulmonary microvascular endothelial cells against peroxidative stress. Antioxid. Redox Signal. 2012, 16:440-451.
44. Power J.H., Shannon J.M., Blumbergs P.C., Gai W.P. Nonselenium glutathione peroxidase in human brain: elevated levels in Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 2002, 161:885-894.
45. Strey C.W., Spellman D., Stieber A., Gonatas J.O., Wang X., Lambris J.D., Gonatas N.K. Dysregulation of stathmin, a microtubule-destabilizing protein, and up-regulation of Hsp25, Hsp27, and the antioxidant peroxiredoxin 6 in a mouse model of familial amyotrophic lateral sclerosis. Am. J. Pathol. 2004, 165:1701-1718.
46. Jin M.H., Lee Y.H., Kim J.M., Sun H.N., Moon E.Y., Shong M.H., Kim S.U., Lee S.H., Lee T.H., Yu D.Y., Lee D.S. Characterization of neural cell types expressing peroxiredoxins in mouse brain. Neurosci. Lett. 2005, 381:252-257.
47. Power J.H., Asad S., Chataway T.K., Chegini F., Manavis J., Temlett J.A., Jensen P.H., Blumbergs P.C., Gai W.P. Peroxiredoxin 6 in human brain: molecular forms, cellular distribution and association with Alzheimer's disease pathology. Acta Neuropathol. 2008, 115:611-622.
48. Goemaere J., Knoops B. Peroxiredoxin distribution in the mouse brain with emphasis on neuronal populations affected in neurodegenerative disorders. J. Comp. Neurol. 2011, 520:258-280.
49. Yata K., Oikawa S., Sasaki R., Shindo A., Yang R., Murata M., Kanamaru K., Tomimoto H. Astrocytic neuroprotection through induction of cytoprotective molecules; a proteomic analysis of mutant P301S tau-transgenic mouse. Brain Res. 2011, 1410:12-23.
50. Krapfenbauer K., Engidawork E., Cairns N., Fountoulakis M., Lubec G. Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res. 2003, 967:152-160.
51. Beal M.F. Oxidatively modified proteins in aging and disease. Free Radic. Biol. Med. 2002, 32:797-803.
52. Pimentel C., Batista-Nascimento L., Rodrigues-Pousada C., Menezes R.A. Oxidative stress in Alzheimer's and Parkinson's diseases: insights from the yeast Saccharomyces cerevisiae. Oxid. Med. Cell. Longev. 2012, 2012:132146.
53. Palacino J.J., Sagi D., Goldberg M.S., Krauss S., Motz C., Wacker M., Klose J., Shen J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 2004, 279:18614-18622.
54. Zhang X.Z., Xiao Z.F., Li C., Xiao Z.Q., Yang F., Li D.J., Li M.Y., Li F., Chen Z.C. Triosephosphate isomerase and peroxiredoxin 6, two novel serum markers for human lung squamous cell carcinoma. Cancer Sci. 2009, 100:2396-2401.
55. Demasi M., Davies K.J. Proteasome inhibitors induce intracellular protein aggregation and cell death by an oxygen-dependent mechanism. FEBS Lett. 2003, 542:89-94.
56. Ling Y.H., Liebes L., Zou Y., Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J. Biol. Chem. 2003, 278:33714-33723.
57. Chandra J. Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies. Antioxid. Redox Signal. 2009, 11:1123-1137.
58. Sofroniew M.V. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009, 32:638-647.
59. 2 gradients across biomembranes. FEBS Lett. 2000, 475:121-126.
60. Paine S.M., Anderson G., Bedford K., Lawler K., Mayer R.J., Lowe J., Bedford L. Pale body-like inclusion formation and neurodegeneration following depletion of 26S proteasomes in mouse brain neurones are independent of alpha-synuclein. PLoS One 2013, 8:e54711.
61. Federico A., Cardaioli E., Da Pozzo P., Formichi P., Gallus G.N., Radi E. Mitochondria, oxidative stress and neurodegeneration. J. Neurol. Sci. 2012, 322:254-262.
62. Fribley A., Zeng Q., Wang C.Y. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol. Cell. Biol. 2004, 24:9695-9704.
63. Choy M.S., Chen M.J., Manikandan J., Peng Z.F., Jenner A.M., Melendez A.J., Cheung N.S. Up-regulation of endoplasmic reticulum stress-related genes during the early phase of treatment of cultured cortical neurons by the proteasomal inhibitor lactacystin. J. Cell. Physiol. 2011, 226:494-510.
64. Xiong R., Siegel D., Ross D. The activation sequence of cellular protein handling systems after proteasomal inhibition in dopaminergic cells. Chem. Biol. Interact. 2013, 204:116-124.
65. Ferreiro E., Baldeiras I., Ferreira I.L., Costa R.O., Rego A.C., Pereira C.F., Oliveira C.R. Mitochondrial- and endoplasmic reticulum-associated oxidative stress in Alzheimer's disease: from pathogenesis to biomarkers. Int. J. Cell Biol. 2012, 2012:23. (Article ID 735206).
66. Abisambra J.F., Jinwal U.K., Blair L.J., O'Leary J.C., Li Q., Brady S., Wang L., Guidi C.E., Zhang B., Nordhues B.A., Cockman M., Suntharalingham A., Li P., Jin Y., Atkins C.A., Dickey C.A. Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation. J. Neurosci. 2013, 33:9498-9507.
67. Bhandary B., Marahatta A., Kim H.R., Chae H.J. An involvement of oxidative stress in endoplasmic reticulum stress and its associated diseases. Int. J. Mol. Sci. 2013, 14:434-456.
68. Omura T., Kaneko M., Okuma Y., Matsubara K., Nomura Y. Endoplasmic reticulum stress and Parkinson's disease: the role of HRD1 in averting apoptosis in neurodegenerative disease. Oxid. Med. Cell. Longev. 2013, 2013:7. (Article ID 239854).
69. Malhotra J.D., Miao H., Zhang K., Wolfson A., Pennathur S., Pipe S.W., Kaufman R.J. Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. PNAS 2008, 105:18525-18530.
70. Samali A., Fitzgerald U., Deegan S., Gupta S. Methods for monitoring endoplasmic reticulum stress and the unfolded protein response. Int. J. Cell Biol. 2010, 2010:11. (Article ID 830307).
71. Pickering A.M., Davies K.J. Degradation of damaged proteins: the main function of the 20S proteasome. Prog. Mol. Biol. Transl. Sci. 2012, 109:227-248.
72. Pickering A.M., Koop A.L., Teoh C.Y., Ermak G., Grune T., Davies K.J. The immunoproteasome, the 20S proteasome and the PA28alphabeta proteasome regulator are oxidative-stress-adaptive proteolytic complexes. Biochem. J. 2010, 432:585-594.
73. Grune T., Catalgol B., Licht A., Ermak G., Pickering A.M., Ngo J.K., Davies K.J. HSP70 mediates dissociation and reassociation of the 26S proteasome during adaptation to oxidative stress. Free Radic. Biol. Med. 2011, 51:1355-1364.
74. Ding Q., Dimayuga E., Keller J.N. Proteasome regulation of oxidative stress in aging and age-related diseases of the CNS. Antioxid. Redox Signal. 2006, 8:163-172.
75. Wang X., Yen J., Kaiser P., Huang L. Regulation of the 26S proteasome complex during oxidative stress. Sci. Signal. 2010, 3:ra88.
76. Shringarpure R., Grune T., Mehlhase J., Davies K.J. Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J. Biol. Chem. 2003, 278:311-318.
77. Kastle M., Reeg S., Rogowska-Wrzesinska A., Grune T. Chaperones, but not oxidized proteins, are ubiquitinated after oxidative stress. Free Radic. Biol. Med. 2012, 53:1468-1477.
78. Hussong S.A., Kapphahn R.J., Phillips S.L., Maldonado M., Ferrington D.A. Immunoproteasome deficiency alters retinal proteasome's response to stress. J. Neurochem. 2010, 113:1481-1490.
79. Tannu N.S., Hemby S.E. Two-dimensional fluorescence difference gel electrophoresis for comparative proteomics profiling. Nat. Protoc. 2006, 1:1732-1742.
80. Rabilloud T., Chevallet M., Luche S., Lelong C. Two-dimensional gel electrophoresis in proteomics: past, present and future. J. Proteomics 2010, 73:2064-2077.
81. Beranova-Giorgianni S. Proteome analysis by two-dimensional gel electrophoresis and mass spectrometry: strengths and limitations. TrAC Trends Anal. Chem. 2003, 22:273-281.